Nicholas A Smith

US Patent:

6699888, Mar 2, 2004

Filed:

Jan 27, 2003

Appl. No.:

10/296907

Inventors:

Ila Sircar - San Diego CA
Yun Feng Xie - San Diego CA
Nicholas Smith - San Diego CA
Paul S. Furth - Bonita CA

Assignee:

Tanabe Seiyaku Co., Ltd. - Osaka

International Classification:

A61K 314439

US Classification:

514341, 5462741

Abstract:

The present invention relates to small molecules according to formula (I) that are potent inhibitors of mediated cell adhesion and which could be useful for the treatment of inflammatory diseases:.

US Patent:

6897225, May 24, 2005

Filed:

Oct 19, 2000

Appl. No.:

10/111110

Inventors:

Ila Sircar - San Diego CA, US
Marshall Morningstar - San Diego CA, US
Paul Furth - Bonita CA, US
Nicholas Smith - San Diego CA, US
Bradley R. Teegarden - San Diego CA, US
Ronald C. Griffith - Escondido CA, US

Assignee:

Tanabe Seiyaku Co., Ltd. - Osaka

International Classification:

C07D487/04
C07D471/04
A61K031/4439
A61K031/4188
A61P019/02

US Classification:

514333, 546256, 5462731, 546121, 5483027, 5483021, 514338, 514387, 544238

Abstract:

The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating αβadhesion mediated conditions in a mammal.

US Patent:

7105548, Sep 12, 2006

Filed:

Dec 13, 2002

Appl. No.:

10/499391

Inventors:

Nicholas D. P. Cosford - San Diego CA, US
Petpiboon Prasit - San Diego CA, US
Jeffrey R. Roppe - Temecula CA, US
Nicholas D. Smith - San Diego CA, US
Lida R. Tehrani - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/44
A61K 31/41
C07D 401/00
C07D 249/04

US Classification:

514340, 514359, 5462684, 548255

Abstract:

Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor—subtype 5 (“mGluR5”) modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.

US Patent:

7253190, Aug 7, 2007

Filed:

Oct 1, 2002

Appl. No.:

10/491613

Inventors:

Nicholas D. P. Cosford - San Diego CA, US
Chixu Chen - San Diego CA, US
Thomas S. Reger - San Diego CA, US
Jeffrey R. Roppe - Temecula CA, US
Nicholas D. Smith - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4439
C07D 401/04

US Classification:

514340, 5462684

Abstract:

Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

US Patent:

7342012, Mar 11, 2008

Filed:

Mar 3, 2005

Appl. No.:

11/070335

Inventors:

Ila Sircar - San Diego CA, US
Paul Furth - Bonita CA, US
Bradley R. Teegarden - San Diego CA, US
Marshall Morningstar - San Diego CA, US
Nicholas Smith - San Diego CA, US
Ronald C. Griffith - Escondido CA, US

Assignee:

Mitsubishi Tanabe Pharma Corporation - Osaka

International Classification:

C07D 487/04
A61K 31/4985

US Classification:

5142332, 544117, 544350, 514249

Abstract:

The present invention relates to a compound of the following formula:.

US Patent:

7365074, Apr 29, 2008

Filed:

Jun 23, 2004

Appl. No.:

10/874835

Inventors:

Nicholas D. Cosford - San Diego CA, US
Jeffrey R. Roppe - Temecula CA, US
Lida R. Tehrani - San Diego NJ, US
Nicholas D. Smith - San Diego CA, US
Brian Stearns - San Diego CA, US
Dehua Huang - San Diego CA, US
Bowei Wang - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 401/06
A61K 31/444

US Classification:

51425203, 51425505, 514256, 544238, 544295, 544333, 544256

Abstract:

In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.

US Patent:

7371767, May 13, 2008

Filed:

Dec 17, 2002

Appl. No.:

10/499393

Inventors:

Nicholas D. P. Cosford - San Diego CA, US
Dehua Huang - San Diego CA, US
Nicholas D. Smith - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4433
A61K 31/427
C07D 277/32
C07D 231/14
C07D 207/325

US Classification:

514340, 514365, 514422, 5462681, 548146, 5483731, 548518

Abstract:

Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

US Patent:

7393959, Jul 1, 2008

Filed:

Mar 31, 2004

Appl. No.:

10/551574

Inventors:

Nicholas D. P. Cosford - San Diego CA, US
Dehua Huang - San Diego CA, US
Jeffrey R. Roppe - Temecula CA, US
Nicholas D. Smith - San Diego CA, US
Lida R. Tehrani - San Diego CA, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

C07D 401/14
A61K 31/4418
A61K 31/4439

US Classification:

546256, 514333

Abstract:

Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R, R, R, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.